Clinical Oversight Review Board (CORB) Criteria for Prescribing

Degarelix (Firmagon)

Notes:

- Quantity limits: No
- * Leuprolide intolerance excludes hot flashes and local injection site reactions.

Non-Formulary **degarelix (Firmagon)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-formulary **degarelix (Firmagon)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of prostate cancer, advanced or metastatic
- Patient is at elast 18 years of age
- Normal QT interval on electrocardiogram

- Either of the following clinical conditions:
  - Documented treatment failure after an adequate trial of leuprolide or intolerance* to leuprolide. Leuprolide trial must include trying the 1-month and a multiple month depot (e.g., 3-month, 4-month, or 6-month)

  -OR-
  - Single dose to prevent testosterone flare associated with ADT initiation for patients with the following:
    - Concern for tumor flare, or metastatic spinal cord compression (MSCC), or anti-androgen intolerance/allergy